HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On August8, 2017, Halozyme Therapeutics, Inc. issued a press release to report its financial results for the second quarter ended June30, 2017. A copy of the press release is attached as Exhibit 99.1, which is furnished under Item 2.02 of this report and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit No. |
Description |
|
|
99.1 |
Press release dated |
August8, 2017 |
HALOZYME THERAPEUTICS INC ExhibitEX-99.1 2 ex9912q2017.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Contacts:Jim Mazzola858-704-8122ir@halozyme.comChris Burton858-704-8352ir@halozyme.com HALOZYME REPORTS SECOND QUARTER 2017 RESULTS– Genentech’s U.S. RITUXAN HYCELA™ Launch Underway; Lilly Doses First Patient in Clinical Study of New Investigational Therapy Combined with Halozyme ENHANZE® Technology – — Total Revenue of $33.8 million with Royalty Revenue Increase of 20 Percent from Prior-Year Period to $14.7 million –SAN DIEGO,…To view the full exhibit click here
About HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO)
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).